Form 4: Lexaria Bioscience Corp. Executive Awarded Stock Options
SEC Form 4 Filing
Vanessa Carle, Secretary of Lexaria Bioscience Corp., reports the acquisition of 15,000 stock options.
Summary
- On May 16, 2025, Vanessa Carle, Secretary of Lexaria Bioscience Corp., filed a Form 4.
- The report details the acquisition of 15,000 stock options with an exercise price of $1.04, exercisable from May 15, 2025, and expiring on May 15, 2030.
- Following this transaction, Carle directly owns 75,000 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports the granting of stock options, a common practice in corporate governance.
Positives
- The granting of stock options to a company officer can be seen as an incentive for future performance.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The granting of stock options could potentially align the interests of the executive with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/26/2021 | Date of grant for 12,500 stock options with an exercise price of $3.00, expiring on 04/26/2026. |
| 06/08/2021 | Date of grant for 5,000 stock options with an exercise price of $3.00, expiring on 06/08/2026. |
| 09/01/2021 | Date of grant for 10,000 stock options with an exercise price of $3.00, expiring on 09/01/2026. |
| 08/29/2022 | Date of grant for 12,500 stock options with an exercise price of $2.91, expiring on 08/29/2027. |
| 10/26/2023 | Date of grant for 10,000 stock options with an exercise price of $1.15, expiring on 10/26/2028. |
| 04/26/2024 | Date of grant for 10,000 stock options with an exercise price of $2.36, expiring on 04/26/2029. |
| 05/15/2025 | Date of transaction: Acquisition of 15,000 stock options with an exercise price of $1.04, expiring on 05/15/2030. |
| 05/16/2025 | Date of Form 4 filing. |
Keywords
stock options, Form 4, insider trading, Lexaria Bioscience Corp., LEXX, Vanessa Carle, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.